Advertisement

Abstract

Sir James Paget described the disease as follows: It begins in middle age or later, is very slow in progress, may continue for many years without influence on the general health, and may give no other trouble than those which are due to the changes of shape, size, and direction of the diseased bones (Paget 1877). Paget's disease is a focal disorder of bone remodeling that occurs in an aging skeleton. Aberrant osteoclast activation is the critical lesion leading to the disease phenotype. Paget's disease leads to impaired structural integrity and distortion of bone, the consequences of which include localized bone pain, deformity, fracture, and early arthritis. Neurological sequelae such as hearing loss, spinal stenosis, and neuropathies can occur, depending on the sites of affected bones. Osteosarcomas arise in pagetic bone in a small number of cases (Seton 2008; Hansen et al. 2006) Both familial and sporadic cases of Paget's disease are caused often by a mutation in SQSTM1. This mutation results in a C→ T transition mutation (P392L) that in turn results in aberrant osteoclast activation (Laurin et al. 2002). However, not all cases are associated with this disease mutation (Kurihara et al. 2007; Morissette et al. 2006). The serum alkaline phosphatase, a marker of osteo-blastic activity, is a good indicator of skeletal extent and activity of Paget's disease. Spot urine assays for N-telopeptide levels have replaced 24-h urine collections for hydroxyproline as a measure of antiresorptive activity. The goal of treating Paget's disease with antiresorptive agents such as the bisphosphonates and calcitonin is to normalize the serum alkaline phosphatase and urine N-telopeptide levels. Bisphosphonates are the treatment of choice. However, calcitonin has a role in the elderly patient with renal insufficiency in whom relief of pain rather than remission is a reasonable outcome. Resistance to the effects of one bisphosphonate does not predict resistance to another.

Keywords

Zoledronic Acid Spinal Stenosis Serum Alkaline Phosphatase Serum Alkaline Phosphatase Level Pagetic Bone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Altman RD. Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med. 1985;79(5): 583–90PubMedCrossRefGoogle Scholar
  2. Brown JP, Chines AA, Myers WR, et al Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 2000; 26(3):263–7PubMedCrossRefGoogle Scholar
  3. Cooper C, Dennison E, Schafheutle K, et al Epidemiology of Paget's disease of bone. Bone 1999;24(5 Suppl):3S–5S.PubMedCrossRefGoogle Scholar
  4. Eyres KS, Marshall P, McCloskey E, et al Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf. 1992;7(2):162–5PubMedCrossRefGoogle Scholar
  5. Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J (Clin Res Ed). 1986;292(6530):1227–9CrossRefGoogle Scholar
  6. Griffiths HJ. Radiology of Paget's disease. Curr Opin Radiol. 1992;4(6):124–8PubMedGoogle Scholar
  7. Haddaway MJ, Davie MW, McCall IW, et al Effect of age and gender on the number and distribution of sites in Paget's disease of bone. Br J Radiol. 2007;80(955):532–6PubMedCrossRefGoogle Scholar
  8. Hansen MF, Seton M, Merchant A. Osteosarcoma in Paget's disease of bone. J Bone Miner Res. 2006;21(Suppl 2):P58–63PubMedCrossRefGoogle Scholar
  9. Hosking D, Lyles K, Brown JP, et al Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res. 2007;22(1):142–8PubMedCrossRefGoogle Scholar
  10. Kurihara N, Hiruma Y, Zhou H, et al Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007;117(1):133–42PubMedCrossRefGoogle Scholar
  11. Laurin N, Brown JP, Morissette J, et al Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582–8PubMedCrossRefGoogle Scholar
  12. Miller PD, Brown JP, Siris ES, et al A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med. 1999;106(5):513–20PubMedCrossRefGoogle Scholar
  13. Morissette J, Laurin N, Brown JP. Sequestosome 1: mutation frequencies, haplotypes, and phenotypes in familial Paget's disease of bone. J Bone Miner Res. 2006;21(Suppl 2):P38–44PubMedCrossRefGoogle Scholar
  14. Paget SJ. On a form of chronic inflammation of bones (osteitis deformans). Med Chir Trans. 1877;LX:29–53Google Scholar
  15. Reid IR, Miller P, Lyles K, et al Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353(9):898–908PubMedCrossRefGoogle Scholar
  16. Reid IR, Nicholson GC, Weinstein RS, et al Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med. 1996;101(4): 341–8PubMedCrossRefGoogle Scholar
  17. Seton M. Paget's disease of bone.. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. 4th ed. Philadelphia: Mosby. 2008Google Scholar
  18. Seton M, Krane SM. Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag. 2007;3(5):913–8PubMedGoogle Scholar
  19. Siris E, Weinstein RS, Altman R, et al Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81(3):961–7PubMedCrossRefGoogle Scholar
  20. Whyte MP, Obrecht SE, Finnegan PM, et al Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347(3):175–84PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Margaret Seton
    • 1
  1. 1.Rheumatology, Allergy and ImmunologyHarvard Medical School, Massachusetts General HospitalBostonUSA

Personalised recommendations